Advertisement

Modern Rheumatology

, Volume 23, Issue 2, pp 318–322 | Cite as

Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)

  • Naoto YokogawaEmail author
  • Akiko Tanikawa
  • Masayuki Amagai
  • Yukihiko Kato
  • Yoko Momose
  • Satoru Arai
  • Hikaru Eto
  • Takaharu Ikeda
  • Fukumi Furukawa
Original Article

Abstract

Background

Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI).

Methods

Twenty-seven patients with lupus-related skin disease who started HCQ at four hospitals were included. Patients were categorized into responders by the CLASI response criteria. The points and the rate of improvement in the CLASI activity score after 16 weeks of treatment were analyzed, focusing on six parameters: systemic lupus erythematosus (SLE), skin manifestations, disease duration, prednisolone, smoking, and severity.

Results

Twenty-seven patients, including 17 with SLE (6 with SLE/Sjögren’s syndrome), were analyzed retrospectively. Twenty-three patients (85 %) were categorized as responders. The mean CLASI activity score improved from 10.1 to 4.5 (p < 0.0001). The improvement rate did not differ in these parameters except for that of annular erythema (81.6 versus 34.3 %, p = 0.036). On multivariate analysis, the baseline CLASI activity score (CLASI ≥9) correlated with the greatest decrease in CLASI activity score (F = 69.7, p < 0.0001).

Conclusions

CLASI is a reliable indicator to evaluate the efficacy of the drug, and HCQ is an effective treatment for Japanese patients with lupus-related skin disease.

Keywords

Systemic lupus erythematosus Cutaneous lupus erythematosus Hydroxychloroquine Cutaneous lupus erythematosus disease area and severity index (CLASI) 

Notes

Acknowledgments

A part of this work was supported by grants from the Ministry of Welfare and Education, Culture, Sports, Science, and Technology of Japan (T.I.). We appreciate Professor Victoria P. Werth (Philadelphia VAMC and University of Pennsylvania, Department of Dermatology) for reviewing this manuscript.

Conflict of interest

The Japanese Hydroxychloroquine Study Group is a volunteer initiative to develop HCQ in Japan and does not have any conflicts of interest. For the preparation of the clinical trial of HCQ, N.Y. and F.F. gave a lecture to Sanofi Aventis KK (lecture fee <US $1,000).

References

  1. 1.
    Yokogawa N. Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/anti-rheumatic drugs; 10. Hydroxychloroquine. Nihon Naika Gakkai Zasshi. 2011;100:2960–5 (in Japanese).Google Scholar
  2. 2.
    Kishimoto M, Deshpande GA, Yokogawa N, Buyon JP, Okada M. Hydroxychloroquine in Japan: a newly rising sun. J Rheumatol. 2012 (in press).Google Scholar
  3. 3.
    Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125:889–94.PubMedGoogle Scholar
  4. 4.
    Yokogawa N, Kato Y, Sugii S, Inada S. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol. 2011 [Epub ahead of print].Google Scholar
  5. 5.
    Ikeda T, Kanazawa N, Furukawa F. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. J Dermatol. 2011 [Epub ahead of print].Google Scholar
  6. 6.
    Gilliam JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis. 1982;8:207–18.PubMedGoogle Scholar
  7. 7.
    Sontheimer RD, McCauliffe DP. Lupus-specific skin disease (cutaneous LE). In: Wallace DJ, Hahn WB, editors. Dubois’ lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 576–620.Google Scholar
  8. 8.
    Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147:203–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.PubMedCrossRefGoogle Scholar
  10. 10.
    Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Albrecht J, Werth VP. Clinical outcome measures for cutaneous lupus erythematosus. Lupus. 2010;19:1137–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;4:CD002954.PubMedGoogle Scholar
  13. 13.
    Dubois E. Antimalarials in the management of discoid and systemic erythematosus. Semin Arthritis Rheum. 1978;8:33–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Tsuchida T. Classification of lupus erythematosus based upon Japanese patients. Autoimmun Rev. 2009;8:453–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Piette EW, Foering KP, Chang AY, Okawa J, Ten Have TR, Feng R, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2011 [Epub ahead of print].Google Scholar
  16. 16.
    Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol. 2009;145:244–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch Dermatol Ges. 2010;8:829–44.PubMedGoogle Scholar
  18. 18.
    Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus. Ann Rheum Dis. 2010;69:20–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62:775–84.CrossRefGoogle Scholar
  20. 20.
    Marmor MF, Kellner U, Lai TY, Lyons JS, American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415–22.PubMedCrossRefGoogle Scholar

Copyright information

© Japan College of Rheumatology 2012

Authors and Affiliations

  • Naoto Yokogawa
    • 1
    Email author
  • Akiko Tanikawa
    • 2
  • Masayuki Amagai
    • 2
  • Yukihiko Kato
    • 3
  • Yoko Momose
    • 4
  • Satoru Arai
    • 4
  • Hikaru Eto
    • 4
  • Takaharu Ikeda
    • 5
  • Fukumi Furukawa
    • 5
  1. 1.Department of Rheumatic DiseasesTokyo Metropolitan Tama Medical CenterFuchuJapan
  2. 2.Department of DermatologyKeio University School of MedicineTokyoJapan
  3. 3.Department of DermatologyTokyo Metropolitan Tama Medical CenterTokyoJapan
  4. 4.Department of DermatologySt. Luke’s International HospitalTokyoJapan
  5. 5.Department of DermatologyWakayama Medical UniversityWakayamaJapan

Personalised recommendations